Multiple Sclerosis News

The FDA granted breakthrough therapy designation to an oral, investigational, brain-penetrant and bioactive Bruton’s tyrosine kinase inhibitor for adults with non-relapsing secondary progressive MS.

WASHINGTON — Herpes zoster vaccination is effective in patients with systemic lupus erythematosus and multiple sclerosis, without increasing the risk for severe lupus flares, according to data presented at ACR Convergence 2024.

Top-line results of a phase 2 clinical trial for an adiposederived autologous mesenchymal stem cell therapy to address mild to moderate relapsing-remitting MS found the treatment improved mental and physical health at 52 weeks.

In pregnant women with MS given ocrelizumab, treatment did not result in infant B-cell depletion after birth, and the drug was virtually undetectable in the bloodstream of mother and child, according to a poster from ECTRIMS 2024.

An independent data monitoring committee has ruled that a phase 3 clinical trial investigating vidofludimus calcium for relapsing MS may continue as originally planned, according to the therapeutic’s manufacturer.

Treatment with diroximel fumarate was linked to lower rates of severe infection compared with anti-CD20 monoclonal antibodies for adults of all ages with MS, according to a poster presented at ECTRIMS.

Early initiation and continuation of Kesimpta in those with relapsing MS was associated with lower rates of disability worsening up to 6 years compared with those who switched medication, according to a presentation at ECTRIMS 2024.

People with MS had an increased risk for bladder, brain and cervical cancers compared with people without MS, according to a new study in Neurology, the medical journal of the American Academy of Neurology.

The FDA has granted investigational device exemption to a clinical-stage health care firm for its proprietary neuroimmune modulation platform for individuals with relapsing-remitting MS, according to the manufacturer.